BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C. World J Hepatol 2010; 2(6): 226-232 [PMID: 21161001 DOI: 10.4254/wjh.v2.i6.226]
URL: https://www.wjgnet.com/1948-5182/full/v2/i6/226.htm
Number Citing Articles
1
Cristina Gluhovschi, Florica Gadalean, Adriana Kaycsa, Manuela Curescu, Ioan Sporea, Gheorghe Gluhovschi, Ligia Petrica, Silvia Velciov, Gheorghe Bozdog, Flaviu Bob, Corina Vernic, Daniel Cioca. Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?Immunopharmacology and Immunotoxicology 2011; 33(4): 744 doi: 10.3109/08923973.2010.551129
2
Hiroaki Okushin, Takeharu Yamamoto, Hiroshi Kishida, Kazuhiko Morii, Koichi Uesaka. Indices of initial hepatitis C virus RNA reduction rate to predict efficacy of interferon‐beta followed by peginterferon plus ribavirin for genotype 1b high viral loadHepatology Research 2014; 44(7): 728 doi: 10.1111/hepr.12182
3
Hayato Uemura, Yoshihito Uchida, Jun‐ichi Kouyama, Kayoko Naiki, Shinpei Yamaba, Akira Fuchigami, Yoichi Saito, Keisuke Shiokawa, Yohei Fujii, Hiroshi Uchiya, Manabu Nakazawa, Satsuki Ando, Masamitsu Nakao, Daisuke Motoya, Kayoko Sugawara, Mie Inao, Yukinori Imai, Nobuaki Nakayama, Tomoaki Tomiya, Satoshi Mochida. Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapyHepatology Research 2018; 48(4): 233 doi: 10.1111/hepr.12980
4
Reina Sasaki, Tatsuo Kanda, Shingo Nakamoto, Yuki Haga, Masato Nakamura, Shin Yasui, Xia Jiang, Shuang Wu, Makoto Arai, Osamu Yokosuka. Natural interferon-beta treatment for patients with chronic hepatitis C in JapanWorld Journal of Hepatology 2015; 7(8): 1125-1132 doi: 10.4254/wjh.v7.i8.1125
5
Yasuhiro Asahina, Namiki Izumi, Makoto Oketani, Hiromitsu Kumada, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu, Hiroshi Yotsuyanagi. Treatment Guidelines of Hepatitis CKanzo 2012; 53(6): 355 doi: 10.2957/kanzo.53.355
6
Hiroaki Okushin, Kazuhiko Morii, Koichi Uesaka, Shiro Yuasa. Study about Zung self-rating depression scale during induction regimen of interferon-β and peginterferon plus ribavirin therapy for chronic hepatitis CKanzo 2011; 52(4): 229 doi: 10.2957/kanzo.52.229
7
Kang Yiu Lai, Wing Yiu George Ng, Fan Fanny Cheng. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virusInfectious Diseases of Poverty 2014; 3(1) doi: 10.1186/2049-9957-3-43
8
Guidelines for the Management of Hepatitis C Virus InfectionHepatology Research 2013; 43(1): 1 doi: 10.1111/hepr.12020
9
Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Tamaki Kobayashi, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Hidenori Kanazawa, Katsuhiko Iwakiri, Choitsu Sakamoto. Lead‐in treatment with interferon‐β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha‐2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotypeJournal of Gastroenterology and Hepatology 2013; 28(3): 443 doi: 10.1111/jgh.12039